A detailed history of ETF Managers Group, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, ETF Managers Group, LLC holds 130,676 shares of BCRX stock, worth $974,842. This represents 0.04% of its overall portfolio holdings.

Number of Shares
130,676
Previous 46,478 181.16%
Holding current value
$974,842
Previous $533,000 104.32%
% of portfolio
0.04%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

Apr 17, 2023

BUY
$7.94 - $11.84 $668,532 - $996,904
84,198 Added 181.16%
130,676 $1.09 Million
Q4 2022

Mar 23, 2023

SELL
$10.5 - $14.2 $88,126 - $119,180
-8,393 Reduced 15.3%
46,478 $533,000
Q3 2022

Nov 14, 2022

SELL
$10.79 - $14.81 $40,721 - $55,892
-3,774 Reduced 6.44%
54,871 $691,000
Q2 2022

Aug 15, 2022

BUY
$7.89 - $17.88 $20,758 - $47,042
2,631 Added 4.7%
58,645 $634,000
Q1 2022

May 13, 2022

BUY
$11.56 - $19.76 $18,854 - $32,228
1,631 Added 3.0%
56,014 $921,000
Q4 2021

Feb 14, 2022

SELL
$11.18 - $15.46 $122,186 - $168,962
-10,929 Reduced 16.73%
54,383 $750,000
Q3 2021

Nov 15, 2021

BUY
$14.21 - $17.65 $183,309 - $227,684
12,900 Added 24.61%
65,312 $939,000
Q2 2021

Aug 16, 2021

SELL
$9.5 - $17.24 $17,670 - $32,066
-1,860 Reduced 3.43%
52,412 $812,000
Q1 2021

May 17, 2021

SELL
$7.37 - $13.61 $232,950 - $430,184
-31,608 Reduced 36.8%
54,272 $542,000
Q4 2020

Feb 16, 2021

SELL
$3.37 - $8.61 $44,042 - $112,524
-13,069 Reduced 13.21%
85,880 $644,000
Q3 2020

Nov 16, 2020

BUY
$3.43 - $5.53 $172,439 - $278,015
50,274 Added 103.29%
98,949 $379,000
Q2 2020

Aug 14, 2020

BUY
$1.9 - $5.61 $92,482 - $273,066
48,675 New
48,675 $242,000

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.39B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track ETF Managers Group, LLC Portfolio

Follow ETF Managers Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of ETF Managers Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on ETF Managers Group, LLC with notifications on news.